Impact of High-Dose Atorvastatin in Coronary Heart Disease Patients Age 65 to 78 Years (original) (raw)
Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)
Ingar Holme
The American Journal of Cardiology, 2009
View PDFchevron_right
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
Jean-Charles Fruchart
Journal of Vascular Surgery, 2005
View PDFchevron_right
Statin therapy in the elderly: A review
Ali Ahmed
Archives of Gerontology and Geriatrics, 2010
View PDFchevron_right
Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
Erin D Michos
Clinical Interventions in Aging, 2010
View PDFchevron_right
Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years
Mary Hanson, Franklin Zieve
Lipids in Health and Disease, 2014
View PDFchevron_right
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study
Vasilios Athyros
Archives of Medical Science, 2013
View PDFchevron_right
Statin therapy in the elderly
Allan Gaw
2003
View PDFchevron_right
Comparison of the efficacy and safety of atorvastatin and fenofibrate in the treatment of mixed hyperlipidemia
Sena Akar
Atherosclerosis, 2000
View PDFchevron_right
Editorial Statin treatment in the elderly: how much do we know?
Giuseppe Montalto
Archives of Medical Science, 2013
View PDFchevron_right
Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention
Vasilios Athyros
Current Medical Research and Opinion, 2002
View PDFchevron_right
Safety of long-term statin therapy: Data from real-world observation in subjects at very high risk
Béla Dr Herczeg
Atherosclerosis, 2017
View PDFchevron_right
Comparison of Efficacy and Safety after Administering High Potency Statin to High Risk Patients: Rosuvastatin 10 mg versus Atorvastatin 20 mg
Mijin Song
Korean Circulation Journal, 2007
View PDFchevron_right
Lipid modifying action of atorvastatin in escalating doses in patients of coronary artery disease
Sajjad Hossain
International Journal of Basic & Clinical Pharmacology, 2014
View PDFchevron_right
High-Dose Atorvastatin in Acute Coronary and Cerebrovascular Syndromes⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology
Carl J Lavie
JACC: Cardiovascular Interventions, 2010
View PDFchevron_right
Suboptimal use of statin therapy in elderly patients with atherosclerosis: A population-based study
Thomas Lindsay
Journal of Vascular Surgery, 2008
View PDFchevron_right
Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
Vasilios Athyros
Current Medical Research and Opinion, 2004
View PDFchevron_right
Statins and the elderly: recent evidence and current indications Aging Clinical and Experimental Research
Bruno Amato, Cinzia Perrino
View PDFchevron_right
Statins for primary cardiovascular prevention in the elderly
Rocío Moreno Toro
Journal of geriatric cardiology : JGC, 2015
View PDFchevron_right
Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study
Robert Rosenson
Atherosclerosis, 2007
View PDFchevron_right
The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years
Mary Hanson, Franklin Zieve
Journal of Geriatric Cardiology, 2011
View PDFchevron_right
Lower cardiovascular mortality with atorvastatin and rosuvastatin vs simvastatin: data from “moderate-intensity” statins users in an observational registry on chronic heart failure (Daunia Heart Failure Registry)
Matteo Di Biase, Antonio Totaro, Natale Brunetti
International Journal of Cardiology, 2015
View PDFchevron_right
Statin therapy and hepatotoxicity: Appraisal of the safety profi le of atorvastatin in hyperlipidemic patients
Saeed Kalantari
View PDFchevron_right
Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
Marwa Kamal
Rational Pharmacotherapy in Cardiology, 2018
View PDFchevron_right
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia
Tineke Smilde
The American Journal of Cardiology, 2005
View PDFchevron_right
Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study)
Andrei Breazna, David Waters, John Larosa
The American Journal of Cardiology, 2008
View PDFchevron_right
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly
Desiderio Favarato
Clinics (São Paulo, Brazil), 2008
View PDFchevron_right
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Eva Lonn
The Lancet, 2019
View PDFchevron_right